Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Cyclin-dependent Kinase 4 (CDK4)
100%
Breast Cancer
100%
Cyclin-dependent Kinase 6 (CDK6)
100%
B-cell Lymphoma 2 (Bcl-2)
100%
Multi-target
100%
Tumor Response
100%
Estrogen
100%
ABT-199
83%
Palbociclib
66%
Combination Therapy
50%
Syngeneic
33%
Fulvestrant
33%
Mammary Tumor Models
33%
Patient-derived Xenograft
16%
Cell Cycle Arrest
16%
Apoptosis
16%
Patient-derived Organoids
16%
Venetoclax
16%
Bcl-2 Family
16%
Cyclin
16%
Apoptotic Cell Death
16%
Functional Assay
16%
Immune System
16%
High Dose
16%
Acquired Resistance
16%
Endocrine Therapy
16%
Breast Cancer Cell Lines
16%
Dephosphorylation
16%
Immunomodulatory Effect
16%
Single Therapy
16%
Senolysis
16%
Anti-PD-1 Therapy
16%
Triple Therapy
16%
CRISPR-Cas9 System
16%
Breast Cancer Relapse
16%
Doublet Therapy
16%
Well Tolerated
16%
Senescent Cells
16%
BCL-2 Inhibitor
16%
Mitigate Loss
16%
Medicine and Dentistry
Neoplasm
100%
Breast Cancer
100%
Cyclin-Dependent Kinase 4
100%
Cyclin-Dependent Kinase 6
100%
Estrogen
100%
Palbociclib
66%
Combination Therapy
50%
Programmed Cell Death
33%
Breast Tumor
33%
Fulvestrant
33%
Clustered Regularly Interspaced Short Palindromic Repeat
16%
Cas9
16%
Cell Cycle Arrest
16%
Xenograft
16%
Cell Cycle Checkpoint
16%
Drug Megadose
16%
Hormone Therapy
16%
Cancer Recurrence
16%
Venetoclax
16%
Breast Cancer Cell Line
16%
Cyclin
16%
Dephosphorylation
16%
Immune System
16%
Patient-Derived Organoid
16%
Nursing and Health Professions
Neoplasm
100%
Breast Cancer
100%
Estrogen
100%
Cyclin Dependent Kinase 4
100%
Cyclin Dependent Kinase 6
100%
Palbociclib
66%
Combination Therapy
50%
Fulvestrant
33%
Breast Tumor
33%
Drug Megadose
16%
Hormonal Therapy
16%
Xenograft
16%
Experimental Design
16%
Cell Death
16%
Cycline
16%
Venetoclax
16%
Cancer Recurrence
16%
Dephosphorylation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Breast Cancer
100%
Cyclin Dependent Kinase 4
100%
Cyclin Dependent Kinase 6
100%
Estrogen
100%
Palbociclib
66%
Combination Therapy
50%
Breast Tumor
33%
Fulvestrant
33%
Venetoclax
16%
Cycline
16%
Endocrine Therapy
16%
Cancer Recurrence
16%
Patient-Derived Organoid
16%